Sanofi has unveiled promising outcomes for its investigational drug, amlitelimab, in treating atopic dermatitis (AD) in patients aged 12 and older. This significant announcement follows the positive results from the COAST 1 study, shared in September 2025, and is further supported by data from the global phase 2 SHORE and COAST 2 studies.
Overview of Amlitelimab
Amlitelimab is a monoclonal antibody that targets the OX40-ligand (OX40L) without depleting T cells. Its unique mechanism aims to modulate the immune response effectively, providing a novel treatment avenue for individuals suffering from moderate to severe AD.
Insights from the SHORE Study
Both the SHORE and COAST 2 studies focused on assessing amlitelimab’s efficacy in a population with moderate to severe atopic dermatitis. Participants received treatment either every four weeks or every 12 weeks, with the SHORE study demonstrating that both dosing schedules, alongside medium-potency topical corticosteroids (TCS) and potentially topical calcineurin inhibitors (TCI), achieved primary and key secondary endpoints compared to the placebo group receiving TCS with or without TCI.
Findings from the COAST 2 Study
In the COAST 2 study, amlitelimab was evaluated as a monotherapy. Remarkably, both dosing schedules met the primary endpoint by week 24, showcasing the drug’s potential as an effective standalone treatment for atopic dermatitis.
Safety and Tolerability Profile
Amlitelimab has exhibited a favorable safety profile across both studies. The rates of treatment-emergent adverse events (TEAEs) were consistent between the amlitelimab groups and the placebo controls, indicating that the treatment is not only effective but also well-tolerated by patients.
Preliminary Results from the ATLANTIS Study
Sanofi has also shared initial findings from the ongoing phase 2 ATLANTIS study. This analysis indicates that four-weekly dosing of amlitelimab led to progressive improvements in skin clearance and reduction in disease severity, with benefits observed extending to week 52. Throughout this observation period, the treatment maintained its well-tolerated status.
Expert Opinions
Houman Ashrafian, Executive Vice President and Head of Research & Development at Sanofi, emphasized the importance of these findings. He noted that the results validate amlitelimab’s innovative mechanism of action, which aims to normalize the immune system without the drawbacks of T-cell depletion. Ashrafian expressed confidence that the data reinforces the drug’s potential for effective treatment with both 12-week dosing and sustained efficacy over time.
Implications for Patients
The advancements in treatment options for atopic dermatitis are particularly significant for patients who have struggled with the condition. Amlitelimab’s targeted approach, coupled with its favorable safety profile, offers hope for improved quality of life for those affected by moderate to severe AD.
Future Directions
As these studies progress, the continued evaluation of amlitelimab will play a crucial role in determining its future in dermatological therapies. The ongoing analysis from the ATLANTIS study and potential future studies may further elucidate its long-term benefits and applicability in clinical settings.
In conclusion, Sanofi’s amlitelimab represents a potential breakthrough in the management of atopic dermatitis. The positive results from recent studies, combined with a strong safety profile, may pave the way for a new standard of care in treating this challenging condition.
- Key Takeaways:
- Amlitelimab shows promise for treating moderate to severe atopic dermatitis in patients aged 12 and older.
- The drug’s unique mechanism targets OX40L without depleting T cells.
- Both SHORE and COAST 2 studies demonstrated significant efficacy and safety.
- Preliminary results from ATLANTIS suggest lasting improvements in skin condition.
- Sanofi’s commitment to this research highlights the potential for innovative treatments in dermatology.
Read more → pmlive.com